News Sentiment

OKYO sentiment intelligence

OKYO Pharma Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.69 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+7.6% over one week, +11.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

H.C. Wainwright Maintains OKYO Pharma(OKYO.US) With Buy Rating, Cuts Target Price to $5

Market Reaction

Price moving ahead of tone

71/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction 7.6% Price confirming higher
Trend fit Trend inactive 11.2% over four weeks
Fair value 1.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 21
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 7
Investing.com 3
Proactive 3
The Globe and Mail 2
GlobeNewswire 2
Proactive financial news 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 9
Analyst action 2
Regulatory and legal 2
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
Simply Wall Street Direct company coverage

OKYO Pharma (Nasdaq:OKYO) - Stock Analysis

OKYO Pharma, a clinical-stage biopharmaceutical company, is advancing its lead candidate, urcosimod, for neuropathic corneal pain (NCP) into a global Phase 3 pivotal trial following positive FDA feedback. Despite this progress, the company faces significant financial risks includ

Tone
Positive 66/100
Event
Market update
Published
09 Jul 2026 20:09
Source
Simply Wall Street
The Globe and Mail Direct company coverage

OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium

OKYO Pharma Limited (OKYO) is set to participate in the Piper Sandler 2026 Virtual Ophthalmology Symposium to discuss its neuropathic corneal pain program. The company recently completed a successful Phase 2 trial of its lead candidate, urcosimod, and plans a 150-patient Phase 2b

Tone
Positive 67/100
Event
Market update
Published
09 Jul 2026 09:11
Source
The Globe and Mail
The Globe and Mail Direct company coverage

OKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal Pain

OKYO Pharma has received positive feedback from the U.S. FDA, validating its strategy to advance urcosimod into a global Phase 3 trial for neuropathic corneal pain. The FDA supported a single-dose Phase 3 study design, potentially allowing for a single-trial registration pathway.

Tone
Positive 73/100
Event
Market update
Published
09 Jul 2026 06:30
Source
The Globe and Mail
Investing.com Direct company coverage

OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial

OKYO Pharma Limited (NASDAQ:OKYO) announced that it received FDA feedback on its clinical development program for urcosimod, a treatment for neuropathic corneal pain, supporting the advancement into a global Phase 3 pivotal trial. The company's shares rose nearly 17% over the pas

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 12:09
Source
Investing.com
Stock Titan Direct company coverage

FDA feedback pushes OKYO Pharma into Phase 3 eye-pain study

OKYO Pharma (Nasdaq: OKYO) announced positive feedback from the FDA Type D meeting, enabling the advancement of urcosimod into a global Phase 3 pivotal trial called NEPTUNE for neuropathic corneal pain (NCP). The FDA's alignment on a single-dose study design and potential single-

Tone
Positive 75/100
Event
Market update
Published
08 Jul 2026 11:09
Source
Stock Titan
Stock Titan Direct company coverage

OKYO Pharma (NASDAQ: OKYO) gets FDA feedback on pivotal Phase 3 NCP trial

OKYO Pharma received positive FDA feedback on its lead drug candidate, urcosimod, for neuropathic corneal pain (NCP), validating its clinical development path. The FDA aligned with a single-dose global Phase 3 pivotal trial design (NEPTUNE) and acknowledged a potential single-tri

Tone
Positive 73/100
Event
Market update
Published
08 Jul 2026 11:09
Source
Stock Titan
GlobeNewswire Direct company coverage

OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain

OKYO Pharma announced positive feedback from its FDA Type D meeting, validating its regulatory and clinical path for urcosimod and accelerating its advancement into a global Phase 3 pivotal trial for Neuropathic Corneal Pain (NCP). The FDA's input clarifies the company's strategy

Tone
Positive 72/100
Event
Regulatory and legal
Published
08 Jul 2026 11:09
Source
GlobeNewswire
GlobeNewswire Direct company coverage

OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

OKYO Pharma announced its participation in the Piper Sandler Virtual Ophthalmology Symposium on Thursday, July 9, 2026. CEO Robert J. Dempsey and Chief Medical Officer Flavio Mantelli MD, PhD will present, discussing the company's clinical-stage biopharmaceutical developments for

Tone
Positive 64/100
Event
Market update
Published
08 Jul 2026 07:09
Source
GlobeNewswire
Stock Titan Direct company coverage

OKYO Pharma CEO to speak at Piper Sandler virtual eye event July 9

OKYO Pharma (Nasdaq: OKYO) will participate in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium on July 9, 2026, at 8:30 AM ET. CEO Robert J. Dempsey and CMO Flavio Mantelli will discuss neuropathic corneal pain and anterior segment eye diseases, a focus

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 10:41
Source
Stock Titan
Stock Titan Direct company coverage

OKYO Pharma (OKYO) to join Piper Sandler 2026 Virtual Ophthalmology Symposium fireside chat

OKYO Pharma (Nasdaq: OKYO) announced its participation in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium on July 9, 2026, at 8:30 AM ET. CEO Robert J. Dempsey and Chief Medical Officer Flavio Mantelli will discuss the company's progress, including the s

Tone
Positive 62/100
Event
Market update
Published
07 Jul 2026 10:41
Source
Stock Titan
Stock Titan Direct company coverage

OKYO (NASDAQ: OKYO) CMO Mantelli reports multi-year option holdings in Form 3

OKYO Pharma Ltd's Chief Medical Officer, Flavio Mantelli, has filed a Form 3 disclosing his holdings of company share options. The filing indicates four option positions, each covering 187,500 underlying shares of common stock with an exercise price of $1.96 per share and an expi

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

OKYO Pharma (OKYO) director adds 300,000-share grant via Panetta Partners

OKYO Pharma Ltd director and 10% owner Gabriele M. Cerrone reported an indirect acquisition of 300,000 shares of common stock through a grant or award. The shares, valued at $1.72 each, are held via Panetta Partners Limited. This transaction increases Cerrone's indirect holdings

Tone
Neutral 50/100
Event
Deals and strategy
Published
11 Jun 2026 09:09
Source
Stock Titan
Stock Titan Direct company coverage

OKYO Pharma (OKYO) CFO receives grant of 40,000 options at $1.85

OKYO Pharma Ltd.'s Chief Financial Officer, Keeren Rameshchandra Shah, was granted options for 40,000 common shares at an exercise price of $1.85 per share. These compensation-related options become exercisable on June 8, 2027, and expire on June 8, 2036. Following this grant, Sh

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

OKYO Pharma (OKYO) director awarded options on 3,500 common shares

OKYO Pharma director Bernard Denoyer was granted options for 3,500 common shares with an exercise price of $1.85 per share, expiring on June 8, 2036. This compensation-related award increases his total option holdings to 35,190 shares. The options vest 25% annually over four year

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 21:10
Source
Stock Titan
ChartMill Direct company coverage

OKYO Stock Price, Quote & Chart | OKYO PHARMA LTD (NASDAQ:OKYO)

This article provides an in-depth financial overview of OKYO Pharma Ltd. (NASDAQ:OKYO), detailing its current stock price of $1.68, recent performance trends, and key statistics like market capitalization and EPS. It also includes technical analysis ratings, analyst forecasts wit

Tone
Positive 66/100
Event
Earnings
Published
29 May 2026 16:10
Source
ChartMill
Yahoo! Finance Canada Direct company coverage

OKYO Pharma expands scientific advisory board with cornea expert - ICYMI

OKYO Pharma recently appointed Dr. Marta Sacchetti to its scientific advisory board to strengthen its clinical programs for neuropathic corneal pain. The company's lead candidate, Urcosimod, is a non-opioid eye drop designed to alleviate pain and inflammation for this debilitatin

Tone
Positive 72/100
Event
Market update
Published
24 May 2026 00:09
Source
Yahoo! Finance Canada
Stock Titan Direct company coverage

OKYO Pharma Ltd (OKYO) CFO details equity and option positions

OKYO Pharma Ltd's CFO, Keeren Rameshchandra Shah, has disclosed his existing equity and option holdings in the company through a Form 3 SEC filing. He directly holds 16,667 shares of common stock. The filing also details numerous option awards, including grants for 31,250 shares

Tone
Neutral 50/100
Event
Market update
Published
22 May 2026 20:09
Source
Stock Titan
VisionMonday.com Direct company coverage

Okyo Pharma Appoints Marta Sacchetti, MD, Ph.D., to Scientific Advisory Board

Okyo Pharma Limited (Nasdaq: OKYO) has expanded its scientific advisory board by appointing Marta Sacchetti, MD, PhD, an associate professor of ophthalmology at Link University in Rome. Dr. Sacchetti's expertise in neuro-inflammatory corneal diseases and ocular surface diseases w

Tone
Positive 70/100
Event
Market update
Published
20 May 2026 12:15
Source
VisionMonday.com
Proactive financial news Direct company coverage

OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment

OKYO Pharma has appointed Dr. Marta Sacchetti, MD, PhD, to its Scientific Advisory Board, enhancing the company's expertise in ophthalmic programs. Dr. Sacchetti brings extensive experience in neuro-inflammatory corneal diseases, aligning with OKYO Pharma's focus on unmet needs i

Tone
Positive 71/100
Event
Market update
Published
19 May 2026 14:40
Source
Proactive financial news